Impotence in patients treated with clofibrate.
Three of our regularly controlled patients suffering from Type IV hyperlipoproteinemia and treated with clofibrate complained of impotence within one year after commencement of treatment with this drug. Two of the patients had previously suffered from myocardial infarction. Two patients observed improvement of the symptom 3 and 4 weeks after interruption of clofibrate therapy; one patient again complained of impotence when clofibrate therapy was resumed. The third patient continued intake of the drug up to the present day, and still complains of impotence.
D000787:Angina Pectoris / Q000209:etiology; D002784:Cholesterol; D002994:Clofibrate / Q000009:adverse effects* / Q000627:therapeutic use; D001728:Dicumarol / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000139:chemically induced*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D014280:Triglycerides / Q000097:blood
D014280:Triglycerides; D001728:Dicumarol; D002784:Cholesterol; D002994:Clofibrate